U.S., Aug. 12 -- ClinicalTrials.gov registry received information related to the study (NCT07116239) titled 'Edoxaban Steady-State PK/PD in Adults With Nephrotic Syndrome' on July 25.
Brief Summary: A study to evaluate the impact of nephrotic syndrome on the steady state pharmacokinetics and pharmacodynamics of edoxaban compared to health volunteers, and whether edoxaban can provide an equivalent anticoagulant effect to enoxaparin sodium.
Study Start Date: Sept., 2025
Study Type: INTERVENTIONAL
Condition:
Nephrotic Syndrome
Hypoalbuminemia
Intervention:
DRUG: Edoxaban 60 mg
film-coated tablet, manufactured by Daiichi Sankyo Europe GmbH
DRUG: Enoxaparin 40 mg
enoxaparin sodium, prefilled syringe of 0.4mL injectable solution, manufa...